Search Results

improvement in OS with less toxicity, because by the time it was published paclitaxel had already been proven to be a superior second agent, and the oncology community felt that intraperitoneal chemotherapy was not necessary in the age of the taxanes. Annual

.gov identifier: NCT01042379 ). The arms consist of one common control arm of standard neoadjuvant chemotherapy with paclitaxel (with an alternate control arm of paclitaxel + trastuzumab or pertuzumab + trastuzumab if HER2-positive) against which other

scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Study of Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard

NACT Several prospective trials have explored whether adding bevacizumab to platinum-based regimens improves outcomes for patients treated with NACT. Preliminary results from GEICO 1205/NOVA found that adding bevacizumab to a standard carboplatin/paclitaxel

epithelial cancer types and stage I disease, first-line systemic therapy generally consists of intravenous platinum-based chemotherapy, with the guidelines recommending paclitaxel at 175 mg/m 2 + carboplatin at an area under the curve (AUC) of 5 to 6 every 3

. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4325#nlm34084-4 . Accessed: July 1, 2009 . 10 Ozols RF Bundy BN Greer BE . Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with

metastatic colorectal cancer . N Engl J Med 2004 ; 350 : 2335 – 2342 . 12. Sandler A Gray R Brahmer J . Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced

cancer, the NCCN Guidelines recommend intraperitoneal chemotherapy for first-line therapy and have been updated to include dose-dense paclitaxel (Taxol, Bristol-Myers Squibb) as a possible treatment option. Dr. Morgan noted that in a recent clinical

and pictilisib, and the dual PI3K/mTOR inhibitor gedatolisib. Initial trials of the AKT inhibitors provided a mixed signal of efficacy. In the phase II PAKT2 trial, capivasertib + paclitaxel improved median OS from 12.6 months to 19.1 months (HR, 0

=.0067) but clinically modest 1.3-month progression-free survival benefit. 9 In the first-line setting of the BOLERO-1/TRIO 019 trial, trastuzumab/paclitaxel/everolimus did not improve progression-free survival overall. However, in the hormone receptor